Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y, Yoshimura K, Nishimoto K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Sugimura H, Suda T. Inoue Y, et al. Among authors: inami n. JAMA Netw Open. 2020 Sep 1;3(9):e2011818. doi: 10.1001/jamanetworkopen.2020.11818. JAMA Netw Open. 2020. PMID: 32955570 Free PMC article.
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T. Nishimoto K, et al. Among authors: inami n. Med Oncol. 2018 Jun 16;35(7):108. doi: 10.1007/s12032-018-1172-x. Med Oncol. 2018. PMID: 29909581 Clinical Trial.
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Akiyama N, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Uto T, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Suda T. Akiyama N, et al. Among authors: inami n. Invest New Drugs. 2019 Jun;37(3):531-537. doi: 10.1007/s10637-019-00747-x. Epub 2019 Feb 21. Invest New Drugs. 2019. PMID: 30790149 Clinical Trial.
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Karayama M, Inui N, Inoue Y, Yoshimura K, Mori K, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Suda T. Karayama M, et al. Among authors: inami n. Cancer Immunol Immunother. 2022 Jan;71(1):203-217. doi: 10.1007/s00262-021-02979-4. Epub 2021 Jun 5. Cancer Immunol Immunother. 2022. PMID: 34091744 Free PMC article.
Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Inoue Y, Inui N, Karayama M, Asada K, Matsuura S, Ikeda M, Uto T, Fujii M, Hashimoto D, Matsui T, Matsuda H, Inami N, Toyoshima M, Kaida Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Enomoto N, Fujisawa T, Suda T. Inoue Y, et al. Among authors: inami n. J Cancer Res Clin Oncol. 2023 Jul;149(7):2963-2974. doi: 10.1007/s00432-022-04193-w. Epub 2022 Jul 14. J Cancer Res Clin Oncol. 2023. PMID: 35834011
Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study.
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Ikeda M, Matsuda H, Inami N, Kaida Y, Funayama S, Ichikawa S, Goshima S, Suda T. Karayama M, et al. Among authors: inami n. J Immunother Cancer. 2023 Jul;11(7):e007056. doi: 10.1136/jitc-2023-007056. J Immunother Cancer. 2023. PMID: 37500182 Free PMC article. Clinical Trial.
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T. Inui N, et al. Among authors: inami n. J Clin Oncol. 2024 Aug 10;42(23):2780-2789. doi: 10.1200/JCO.24.00278. Epub 2024 Jun 4. J Clin Oncol. 2024. PMID: 38833659 Free PMC article. Clinical Trial.
Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.
Karayama M, Inui N, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Asada K, Nishimoto K, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Ikeda M, Matsuda H, Inami N, Kaida Y, Funayama S, Ichikawa S, Goshima S, Suda T. Karayama M, et al. Among authors: inami n. BMC Pulm Med. 2024 Oct 8;24(1):495. doi: 10.1186/s12890-024-03284-3. BMC Pulm Med. 2024. PMID: 39379903 Free PMC article. Clinical Trial.
62 results